| IEX |
Report |
Adjusted EPS (Q2 2026) |
BEAT |
pred ~$2.14 vs. cons $2.10 |
MEDIUM |
| IEX |
Report |
Revenue (Q2 2026) |
IN-LINE |
pred ~$911M vs. cons $904.8M |
MEDIUM |
| IEX |
Report |
Adjusted EBITDA margin (Q2 2026) |
IN-LINE |
pred ~27.0% vs. cons 26.75% |
MEDIUM |
| IEX |
Guide |
Adjusted EPS guidance |
LOWER |
guide ~$2.18 vs. cons $2.19 (Q3 2026) |
MEDIUM |
| IEX |
Guide |
Adjusted EPS guidance |
BETTER |
guide ~$8.53 vs. cons $8.48 (FY2026) |
MEDIUM |
| IEX |
Guide |
Organic sales growth guidance |
UNCHANGED |
guide ~3.5% vs. cons 3.5% (FY2026) |
HIGH |
| IEX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| IEX |
Return |
5-day cumulative residual |
+0.6% (FADE) |
The Q2 EPS beat and modest FY2026 raise support the initial reaction, but Q3 guidance of ~$2.18 versus $2.19 consensus limits upward revisions; the out-period math leaves little incremental FY2026 estimate upside after absorbing the Q2 beat. |
LOW |